Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.
Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe website has been updated to version v2.13.3, with new additions dated from December 10 to December 12, 2024, while the previous version v2.13.2 and several earlier dates have been removed.SummaryDifference0.5%
- Check15 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information on who to contact for questions about joining the study and where it is taking place, with a revision from v2.12.2 to v2.13.2.SummaryDifference2%
- Check22 days agoChange DetectedRecent additions include three new dates in November 2024, while three earlier dates from September and October 2024 have been removed.SummaryDifference0.5%
- Check29 days agoChange DetectedSeveral links to external resources related to viral infections, rare diseases, and clinical studies have been removed, which may impact access to important health information.SummaryDifference3%
- Check36 days agoChange DetectedNew resources have been added, including links to MedlinePlus, NIH, and clinical studies, enhancing access to information on viral infections and rare diseases.SummaryDifference0.4%
- Check43 days agoChange DetectedThe website has been updated to version v2.12.2, introducing new features for downloading data in various formats and allowing users to select specific fields for export.SummaryDifference3%
Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.